Evidence map›Paper›PMID 40116486›Full record

ArticleCancer medicine2025

Upregulation of RIG-I is Critical for Responsiveness to IFN-α Plus Anti-PD-1 in Colorectal Cancer.

Haihang Nie, Shilin Fang, Rui Zhou, Yifan Jia, Jingkai Zhou, Yumei Ning, Yali Yu, Yuntian Hong, Fei Xu, Qiu Zhao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Haihang NieDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Shilin FangDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.
Rui ZhouDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yifan JiaDepartment of Pain, Renmin Hospital of Wuhan University, Wuhan, China.
Jingkai ZhouDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yumei NingDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yali YuDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yuntian HongDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Fei XuDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Qiu ZhaoDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID https://orcid.org/0000-0002-3230-6077
Jiayan NieDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Fan WangDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.

Funding

Hubei Province health and family planning scientific research project WJ2023M065Natural Science Foundation of Hubei, China 2023AFB203the Guidance Project of Scientific Research Plan of the Health Commission of Hubei Province WJ2023F012the National Natural Science Foundation of China 82303248the National Natural Science Foundation of China 82403279The Science and Technology Innovation Cultivation Fund of Zhongnan Hospital, Wuhan University CXPY2024002Wuhan University Independent Scientific Research Young Teachers Project 2042023kf0086
6 · The paper itself

Abstract

backgroundsImmunotherapy is a promising and effective approach that has achieved significant curative effects in colorectal cancer (CRC). Recently, retinoic acid-inducible gene I (RIG-I) has been shown to play a critical role in tumor immunity. However, the correlation between RIG-I and immunotherapy in CRC remains unclear.

methodsRIG-I expression was measured in CRC and normal samples based on analysis of the public databases, a tissue microarray, and CRC cell lines. The correlation between RIG-I and immune microenvironment was explored using well-established biological algorithms and in vitro and in vivo experiments.

resultsWe discovered that RIG-I expression was downregulated in CRC compared with normal samples. The bioinformatic algorithms indicated that high RIG-I-expressing samples showed a positive correlation with IFN-α response and enrichment of antitumor immune cells, especially CD8+ T cells. Furthermore, knockdown of RIG-I expression efficiently reduced the cell death, STAT1 phosphorylation, and CXCL10/11 expression induced by IFN-α in CRC cells. Finally, an in vivo study showed that the infiltration of CD3+ CD8+ T cells was significantly decreased in the RIG-I knockout group. An animal model further confirmed that the inhibition of tumor growth induced by IFN-α plus anti-PD-1 therapy was dependent on RIG-I expression.

conclusionRIG-I is a promising biomarker for CRC immunotherapy, which provides a novel concept for combinatorial immunotherapy.

Indexed as

Colorectal NeoplasmsDEAD Box Protein 58Immune Checkpoint InhibitorsInterferon-alphaProgrammed Cell Death 1 ReceptorAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiceReceptors, ImmunologicSTAT1 Transcription FactorTumor MicroenvironmentDEAD Box Protein 58Immune Checkpoint InhibitorsInterferon-alphaPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, ImmunologicRIGI protein, humanSTAT1 Transcription Factoranti‐PD‐1bioinformatic analysiscolorectal cancercombinatorial immunotherapyinterferon‐αRIG‐I

Identifiers

PMID40116486
PMCPMC11926914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.